BioCryst Pharmaceuticals, Inc. (BCRX)
Current
- (-)
After Hours
Rating Performance
Rating Return
+0.0% vs
Rating Accuracy
0.0% (0 of 0*)
Rating Return
+22.37% vs
Rating Accuracy
100.0% (1 of 1*)
Rating Return
+22.37% vs
Rating Accuracy
50.0% (1 of 2*)
Rating Return
+64.87% vs
Rating Accuracy
60.0% (3 of 5*)
FV Performance
FV Accuracy
7 Hits (100.0% Hit Rate)
FV Avg. Distance
+59.04%
FV Accuracy
13 Hits (100.0% Hit Rate)
FV Avg. Distance
+29.52%
FV Accuracy
14 Hits (56.0% Hit Rate)
FV Avg. Distance
+34.12%
FV Accuracy
25 Hits (51.02% Hit Rate)
FV Avg. Distance
+26.68%
About
CEO
Jon P. Stonehouse
Employees
140
Industry
-
Sector
-
Headquarters
Durham
Exchange
NASDAQ
Website
http://www.biocryst.comSummary Stats
Market Cap
1.89B
Revenue
188M
Net Income
-194M
EPS
-$1.07
Price-to-Earnings
-9.51
Price-to-Book
-11.49
Debt-to-Equity
-4.21
News
Analyst Ratings
Price targets projected by 9 analysts
High
$13.00
Average
$8.61
Low
$4.00
Ratings calculated by 10 analysts
Buy
8
Hold
2
Sell
0
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q1 2022
Missed by -$0.03
-$0.40 -8.1%
-0.37
-0.36
Down 11%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--